Zolmitriptan
Zolmitriptan is a triptan medicine used to treat a migraine attack once it has started, available as tablets, orally disintegrating tablets and a nasal spray.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 22 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Zolmitriptan is a triptan that stops a migraine attack once it starts (it does not prevent them), acting on serotonin receptors to narrow swollen blood vessels in the head and calm pain and inflammation signals; around since about 1997 and available generically, it is a common first-choice prescription. Most people tolerate it well, and the side effect they notice most is a brief tightness or pressure in the neck, throat or jaw, plus some dizziness. Because it narrows blood vessels, it is not safe with heart disease, a past stroke or mini-stroke, or uncontrolled high blood pressure, and chest pain that is severe or will not go away needs emergency help.
Clinical pearls
- The orally disintegrating tablet melts on the tongue without water, and the nasal spray helps when nausea makes swallowing hard.
- If it helps but the migraine returns, a second dose may be allowed after 2 hours, within the daily maximum.
- Leave 24 hours between zolmitriptan and any other triptan, such as sumatriptan, or an ergot medicine like dihydroergotamine.
- Cimetidine (Tagamet) raises zolmitriptan levels and SSRI or SNRI antidepressants add serotonin syndrome risk, so have your pharmacist screen your list.
Patient information guide A plain-language walkthrough of Zolmitriptan, written from its FDA label.
What Zolmitriptan is used for
▾
Zolmitriptan is used to treat migraine attacks once they begin.
- Acute migraine with or without aura in adults: tablets, orally disintegrating tablets and nasal spray.
- Acute migraine with or without aura in teens 12 and older: nasal spray products only (Zomig and zolmitriptan nasal spray).
- Not for preventing migraine, and not shown to work for cluster headache.
How Zolmitriptan works
▾
Zolmitriptan is a triptan. It binds to serotonin 5-HT 1B/1D receptors on blood vessels inside the head and on nerves of the trigeminal system, which carries head pain signals. This narrows blood vessels and reduces release of inflammatory chemicals that contribute to migraine pain.
Its active breakdown product also binds these receptors and may add to the effect.
Zolmitriptan dosage
▾
Zolmitriptan is taken by mouth as a tablet or orally disintegrating tablet, or sprayed in the nose, at the start of a migraine. If the migraine isn't gone after 2 hours, or it returns, a second dose may be used, up to a daily limit. Food doesn't significantly change how it is absorbed.
- Some orally disintegrating tablet labels say not to break the tablet.
- Nasal spray dosing is adjusted to the individual.
- Follow your prescriber and label for your exact dose and limits.
Dosing details from the FDA-approved label
From the Zolmitriptan prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Migraine with or without aura (adults) – zolmitriptan tablets and orally disintegrating tablets
- Recommended starting dose 1.25 mg or 2.5 mg
- If the migraine has not resolved by 2 hours, or returns after a transient improvement, a second dose may be administered at least 2 hours after the first dose
- Maximum: Maximum single dose 5 mg; maximum daily dose 10 mg in any 24-hour period
- Safety in treating an average of more than three migraines in a 30-day period has not been established; orally disintegrating tablets must not be broken
- Migraine – ZOMIG nasal spray (adult and pediatric patients 12 years of age and older)
- Recommended starting dose 2.5 mg
- Dose should be adjusted on an individual basis
- Another dose may be administered at least 2 hours after the previous dose if migraine has not resolved or returns
- Maximum: Maximum single dose 5 mg; not to exceed 10 mg in any 24-hour period
- Safety in treating an average of more than four headaches in a 30-day period has not been established
- Moderate to severe hepatic impairment – tablets and orally disintegrating tablets
- 1.25 mg (one-half of one 2.5 mg tablet) recommended
- Maximum: Total daily dose no more than 5 mg per day in severe hepatic impairment
- Because of increased zolmitriptan blood levels and elevation of blood pressure; orally disintegrating tablets are not recommended in moderate or severe hepatic impairment because they should not be broken in half
- Hepatic impairment – ZOMIG nasal spray
- Not recommended in moderate to severe hepatic impairment
- Dosage in mild hepatic impairment is the same as for normal hepatic function
- Because of increased zolmitriptan blood levels and elevation of blood pressure
- Patients taking cimetidine
- Limit the maximum single dose to 2.5 mg
- Maximum: Not to exceed 5 mg in any 24-hour period
- Applies when co-administered with cimetidine
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Recommended starting dose: 1.25 mg or 2.5 mg (2.1) Maximum single dose: 5 mg (2.1) May repeat dose after 2 hours if needed; not to exceed 10 mg in any 24-hour period (2.1) Moderate or Severe Hepatic Impairment: 1.25 mg recommended (2.3 , 8.6) 2.1 Dosing Information The recommended starting dose of zolmitriptan tablets is 1.25 mg or 2.5 mg. The 1.25 mg dose can be achieved by manually breaking the functionally-scored 2.5 mg tablet in half. The maximum recommended single dose of zolmitriptan tablets is 5 mg. In controlled clinical trials, a greater proportion of patients had headache response following a 2.5 mg or 5 mg dose than following a 1 mg dose. There was little added benefit from the 5 mg dose compared to the 2.5 mg dose, but adverse reactions were more frequent with the 5 mg dose. If the migraine has not resolved by 2 hours after taking zolmitriptan tablets, or returns after a transient improvement, a second dose may be administered at least 2 hours after the first dose. The maximum daily dose is 10 mg in any 24-hour period. The safety of zolmitriptan tablets in the treatment of an average of more than three migraines in a 30-day period has not been established. 2.3 Dosing in Patients with Hepatic Impairment The recommended dose of zolmitriptan tabletsin patients with moderate to severe hepatic impairment is 1.25 mg (one-half of one 2.5 mg zolmitriptan tablet) because of increased zolmitriptan blood levels in these patients and elevation of blood pressure in some of these patients. Limit the total daily dose in patients with severe hepatic impairment to no more than 5 mg per day. 2.4 Dosing in Patients taking Cimetidine If zolmitriptan tablets are co-administered with cimetidine, limit the maximum single dose of zolmitriptan tablets to 2.5 mg, not to exceed 5 mg in any 24-hour period [see Drug Interactions (7.5) , Clinical Pharmacology (12.3) ] .
2.1 Dosing Information The recommended starting dose of zolmitriptan tablets is 1.25 mg or 2.5 mg. The 1.25 mg dose can be achieved by manually breaking the functionally-scored 2.5 mg tablet in half. The maximum recommended single dose of zolmitriptan tablets is 5 mg. In controlled clinical trials, a greater proportion of patients had headache response following a 2.5 mg or 5 mg dose than following a 1 mg dose.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Zolmitriptan side effects
▾
Most side effects are mild and tend to be dose related.
Common side effects
- Pain, tightness or pressure in the neck, throat or jaw
- Dizziness
- Tingling or numbness (paresthesia)
- Weakness or tiredness (asthenia)
- Sleepiness
- Feeling warm or cold
- Nausea
- Dry mouth
When to get medical help
- Chest pain or tightness that is severe or doesn't go away, or signs of a heart attack, such as symptoms that start within hours of a dose
- Fast or irregular heartbeat or other heart rhythm problems
- Signs of stroke or bleeding in the brain
- Stomach pain with bloody diarrhea, or cold, numb or painful fingers and toes
- Vision loss or major vision changes
- Agitation, hallucinations, fast heartbeat, fever, overactive reflexes, nausea, vomiting or diarrhea, which may be serotonin syndrome
- Swelling of the face, lips or throat, or trouble breathing (signs of a severe allergic reaction)
- Headaches on 10 or more days a month, or daily headaches that get worse with migraine medicine
Seek help for severe chest pain, irregular heartbeat, stroke symptoms, severe stomach pain with bloody diarrhea, vision loss, signs of serotonin syndrome, or allergic reactions like facial swelling.
Zolmitriptan warnings and precautions
▾
- Heart and blood vessel risks: heart attack, artery spasm, dangerous rhythm problems and stroke have been reported, sometimes in people without known heart disease.
- Blood pressure: it can raise blood pressure, so it should be monitored.
- Serotonin syndrome: possible, especially with antidepressants.
- Medication overuse headache: from using migraine drugs 10 or more days a month.
- Diagnosis: use only when migraine is clearly diagnosed. Other serious conditions should be ruled out for unusual headaches.
Zolmitriptan interactions
▾
Several medicines can clash with zolmitriptan.
- Ergot medicines and other triptans: wait 24 hours, because blood vessel narrowing can add up.
- MAO-A inhibitors: not allowed together or within 2 weeks, since they raise zolmitriptan levels.
- SSRIs, SNRIs, tricyclics: risk of serotonin syndrome.
- Cimetidine: doubles zolmitriptan levels, so the dose limit is lowered.
Interactions listed in the FDA-approved label
From the Zolmitriptan prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Ergot-containing drugs (ergotamine-containing or ergot-type medications such as dihydroergotamine or methysergide): Ergot-containing drugs have been reported to cause prolonged vasospastic reactions, and these effects may be additive. Use within 24 hours of each other is contraindicated.
- MAO-A inhibitors: MAO-A inhibitors increase the systemic exposure of zolmitriptan and its active N-desmethyl metabolite. Use in patients receiving MAO-A inhibitors is contraindicated.
- Other 5-HT1B/1D agonists (including triptans): The risk of vasospastic reactions may be additive. Concomitant use within 24 hours of zolmitriptan treatment is contraindicated.
- Selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs): Cases of life-threatening serotonin syndrome have been reported during co-administration of triptans and SSRIs or SNRIs.
- Cimetidine: The half-life and blood levels of zolmitriptan and its active N-desmethyl metabolite were approximately doubled. Limit the maximum single dose of zolmitriptan to 2.5 mg, not to exceed 5 mg in any 24-hour period.
Read the label’s full interactions text
7 DRUG INTERACTIONS 7.1 Ergot-containing Drugs Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and zolmitriptan tablets within 24 hours of each other is contraindicated [see Contraindications (4) ] . 7.2 MAO-A Inhibitors MAO-A inhibitors increase the systemic exposure of zolmitriptan and its active N-desmethyl metabolite. Therefore, the use of zolmitriptan tablets in patients receiving MAO-A inhibitors is contraindicated [see Contraindications (4) , Clinical Pharmacology (12.3) ] . 7.3 5-HT1B/1D agonists Concomitant use of other 5-HT 1B/1D agonists (including triptans) within 24 hours of zolmitriptan tablets treatment is contraindicated because the risk of vasospastic reactions may be additive [see Contraindications (4) ] . 7.4 Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors Cases of life-threatening serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions (5.7) ] . 7.5 Cimetidine Following administration of cimetidine, the half-life and blood levels of zolmitriptan and its active N-desmethyl metabolite were approximately doubled [see Clinical Pharmacology (12.3) ] . If cimetidine and zolmitriptan tablets are used concomitantly, limit the maximum single dose of zolmitriptan tablets to 2.5 mg, not to exceed 5 mg in any 24-hour period [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] .
7.1 Ergot-containing Drugs Ergot-containing drugs have been reported to cause prolonged vasospastic reactions.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Zolmitriptan
▾
- Heart disease, stroke or TIA, peripheral vascular disease, ischemic bowel disease, Wolff-Parkinson-White syndrome or uncontrolled high blood pressure: do not use.
- Multiple heart risk factors: a heart check may be needed first.
- Moderate to severe liver problems: nasal spray not recommended, lower tablet dose recommended.
- Pregnancy: animal studies showed fetal harm. Discuss with your doctor.
- Breastfeeding: no human data. Discuss with your doctor.
- Children: nasal spray studied in ages 12 to 17. Not established under 12.
- Older adults: cautious dosing, starting low.
Zolmitriptan overdose
▾
There is no experience with acute overdose. In studies, people who took a large single dose commonly felt sedated. There is no specific antidote, so care focuses on supporting breathing and the heart, with monitoring for at least 15 hours or until symptoms resolve. Contact poison control or emergency services if you take too much.
How your body processes Zolmitriptan
▾
The nasal spray is absorbed quickly, with zolmitriptan detected in the blood by 5 minutes and peak levels usually by about 3 hours. Zolmitriptan is converted to an active breakdown product that may add substantially to its effect. Its half-life is about 3 hours, and most of it leaves through the urine and feces.
How to store Zolmitriptan
▾
Store at 20°C to 25°C (68°F to 77°F) . Protect from light and moisture. Dispense in a tight, light-resistant closed container.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Zolmitriptan
50 supplements and herbal products have documented interactions with Zolmitriptan in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 8
- Moderate · 31
- Minor · 11
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Zolmitriptan: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Zolmitriptan — the kind of thing our pharmacy team would talk through with you at the counter.
What is zolmitriptan for?
▾
How do I take it?
▾
What side effects should I expect?
▾
Can I take it with my antidepressant?
▾
Who shouldn't take it?
▾
Is it safe during pregnancy?
▾
Is Zolmitriptan available over the counter?
▾
When was Zolmitriptan first available?
▾
Who makes Zolmitriptan?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Zolmitriptan on HelloPharmacist
Zolmitriptan forms and strengths (how it comes)
Zolmitriptan is available in 3 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Zolmitriptan inactive ingredients by manufacturer.
Tablet
How this form is used
- Zomig tablets are used for acute migraine with or without aura in adults.
- Zolmitriptan tablets are used for acute migraine with or without aura in adults.
- Zomig tablets: a second dose may be taken after at least 2 hours if the migraine returns or isn't gone.
- Zolmitriptan tablets: a lower dose is recommended with moderate or severe liver impairment.
Orally disintegrating tablet
How this form is used
- Zolmitriptan orally disintegrating tablets are used for acute migraine with or without aura in adults.
- Zolmitriptan orally disintegrating tablets: some labels say not to break the tablet.
- Zolmitriptan orally disintegrating tablets: a second dose may be taken after at least 2 hours if needed, within the daily maximum.
- Zolmitriptan orally disintegrating tablets: a lower dose is recommended with moderate or severe liver impairment.
Nasal spray
How this form is used
- Zomig nasal spray is used for acute migraine with or without aura in adults and teens 12 and older.
- Zolmitriptan nasal spray is used for acute migraine with or without aura in adults and teens 12 and older.
- Zomig nasal spray: another dose may be given after at least 2 hours if the migraine isn't gone or returns.
- Zomig nasal spray: dose is adjusted for the individual, and it is not recommended with moderate to severe liver problems.
- Zolmitriptan nasal spray: safety for treating more than four headaches on average in 30 days has not been established.
Zolmitriptan on the U.S. market: products, makers and brands
How Zolmitriptan appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
20 companies list 46 Zolmitriptan product records with the FDA, mostly as tablet, orally disintegrating tablet, nasal spray; the earliest marketing or approval year on record is 1997. Brand names on the directory include Zomig-ZMT, Zomig, Zolmitriptan OD; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (10) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Zolmitriptan is used (Medicaid data)
A general measure of how commonly Zolmitriptan is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Zolmitriptan is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Zolmitriptan prescribed? Of the 1,601 medications we measure, Zolmitriptan ranks #756 by Medicaid prescriptions — more than 53% of them.
Utilization by Zolmitriptan product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
zolmitriptan 5 MG Oral Tablet Most dispensed
Summed across the 6 of 29 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 200194
zolmitriptan 5 MG/ACTUAT Nasal Spray
Summed across the 3 of 12 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 402000
zolmitriptan 5 MG Disintegrating Oral Tablet
Summed across the 3 of 25 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 351134
zolmitriptan 2.5 MG Oral Tablet
Summed across the 4 of 29 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 200193
zolmitriptan 2.5 MG Disintegrating Oral Tablet
Summed across the 3 of 25 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 284201
zolmitriptan 2.5 MG/ACTUAT Nasal Spray
Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1483677
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Zolmitriptan, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 21 of 123 listed Zolmitriptan NDCs with Medicaid activity.
Compare Zolmitriptan products
A representative set of FDA-listed product records for Zolmitriptan — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Nasal spray | ||||
| 2.5 mg | Nasal | Amneal Pharmaceuticals NY LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 5 mg | Nasal | Amneal Pharmaceuticals NY LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 5 mg | Nasal | Bryant Ranch Prepack × 3 listings | ANDA | View NDC → |
| 5 mg | Nasal | Padagis Israel Pharmaceuticals Ltd | ANDA | View NDC → |
| 💊Orally disintegrating tablet | ||||
| 2.5 mg | Oral | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 5 mg | Oral | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| 5 mg | Oral | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| 2.5 mg | Oral | AvKARE | ANDA | View NDC → |
| 5 mg | Oral | AvKARE | ANDA | View NDC → |
| 2.5 mg | Oral | Glenmark Pharmaceuticals Inc., USA | ANDA | View NDC → |
| 5 mg | Oral | Glenmark Pharmaceuticals Inc., USA | ANDA | View NDC → |
| 2.5 mg | Oral | Jubilant Cadista Pharmacuticals Inc. | ANDA | View NDC → |
| 5 mg | Oral | Jubilant Cadista Pharmacuticals Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 5 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 2.5 mg | Oral | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 5 mg | Oral | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 💊Tablet | ||||
| 2.5 mg | Oral | Ajanta Pharma USA Inc. | ANDA | View NDC → |
| 5 mg | Oral | Ajanta Pharma USA Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 5 mg | Oral | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| 5 mg | Oral | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| 2.5 mg | Oral | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 5 mg | Oral | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 2.5 mg | Oral | Asclemed USA, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Asclemed USA, Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 5 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 2.5 mg | Oral | BluePoint Laboratories | ANDA | View NDC → |
| 5 mg | Oral | BluePoint Laboratories | ANDA | View NDC → |
| 2.5 mg | Oral | Cipla USA Inc. | ANDA | View NDC → |
| 5 mg | Oral | Cipla USA Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Direct_Rx | ANDA | View NDC → |
| 5 mg | Oral | Direct_Rx | ANDA | View NDC → |
| 2.5 mg | Oral | Glenmark Pharmaceuticals Inc.,USA | ANDA | View NDC → |
| 5 mg | Oral | Glenmark Pharmaceuticals Inc.,USA | ANDA | View NDC → |
| 2.5 mg | Oral | Medstone Pharma LLC | ANDA | View NDC → |
| 5 mg | Oral | Medstone Pharma LLC | ANDA | View NDC → |
| 2.5 mg | Oral | PLD Acquisitions LLC DBA Avma Pharma Solutions | ANDA | View NDC → |
| 5 mg | Oral | PLD Acquisitions LLC DBA Avma Pharma Solutions | ANDA | View NDC → |
| 2.5 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
Showing 46 of 46 products — FDA National Drug Code Directory. See every product, package size and price: browse all 46 Zolmitriptan NDCs →
Zolmitriptan side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Zolmitriptan — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Zolmitriptan in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Zolmitriptan FDA approval history
How Zolmitriptan went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Zolmitriptan recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Zolmitriptan recalls since July 2021.
✅No Zolmitriptan recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 135775 3 dose forms · 6 strengths
-
Dose form (SCDF) Disintegrating Oral Tablet RxCUI 374653In current FDA listings -
Dose form (SCDF) Nasal Spray RxCUI 402420In current FDA listings -
Dose form (SCDF) Oral Tablet RxCUI 374363In current FDA listings
Look up RxCUI 135775 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Zolmitriptan supply and shortage status
Whether Zolmitriptan is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Zolmitriptan costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet, Film Coated · Oral | 2.5 mg | $1.02 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 5 mg | $1.35 per tablet | NDC details & price history |
| Tablet · Oral | 5 mg | $1.35 per tablet | NDC details & price history |
| Tablet · Oral | 2.5 mg | $1.02 per tablet | NDC details & price history |
| Spray · Nasal | 5 mg | $44.04 each | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Zolmitriptan brand names
Zolmitriptan is sold under 3 brand names in the FDA directory — Zomig-ZMT, Zomig, Zolmitriptan OD. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Zolmitriptan: manufacturers and labelers
20 companies list Zolmitriptan products with the FDA. By number of product records, the largest are Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Glenmark Pharmaceuticals Inc., USA. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Zolmitriptan drug class (RxNorm)
Zolmitriptan belongs to the Serotonin-1b and Serotonin-1d Receptor Agonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Zolmitriptan page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. PLD Acquisitions LLC DBA Av�ma Pharma Solutions is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →